Novavax (XSWX:NVAX) Cyclically Adjusted Book per Share: CHF-1.99 (As of Mar. 2026)


XSWX:NVAX Novavax Inc XSWX:NVAX
50 GF Score
Price CHF7.61
GF Value CHF3.14
! 7 Warning Signs
View Full Analysis

What is Novavax Cyclically Adjusted Book per Share?

Novavax XSWX:NVAX -1.78% 50 Cyclically Adjusted Book per Share is CHF-1.99 as of Mar. 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 50/100 and a GF Value™ of CHF3.14. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novavax's adjusted book value per share for the three months ended in Mar. 2026 was CHF-0.693. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF-1.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novavax's average Cyclically Adjusted Book Growth Rate was -472.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novavax was 8.10% per year. The lowest was -41.40% per year. And the median was -5.10% per year.

As of today (2026-07-07), Novavax's current stock price is CHF7.612. Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was CHF-1.99. Novavax's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 2.56.


Novavax  (XSWX:NVAX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 2.56.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novavax Cyclically Adjusted Book per Share Related Terms


Novavax Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novavax's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cyclically Adjusted Book per Share Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.99

XSWX:NVAX vs MPLT, COAG, INBX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.


XSWX:NVAX
50GF Score
Novavax Inc XSWX:NVAX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.693/330.2130*330.2130
=-0.693

Current CPI (Mar. 2026) = 330.2130.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201606 7.882 241.018 10.799
201609 3.572 241.428 4.886
201612 -0.417 241.432 -0.570
201703 -2.062 243.801 -2.793
201706 -3.944 244.955 -5.317
201709 -4.602 246.819 -6.157
201712 -6.213 246.524 -8.322
201803 -5.434 249.554 -7.190
201806 -4.550 251.989 -5.962
201809 -6.410 252.439 -8.385
201812 -8.666 251.233 -11.390
201903 -6.418 254.202 -8.337
201906 -7.808 256.143 -10.066
201909 -7.366 256.759 -9.473
201912 -5.650 256.974 -7.260
202003 -0.427 258.115 -0.546
202006 2.868 257.797 3.674
202009 1.548 260.280 1.964
202012 7.853 260.474 9.956
202103 13.046 264.877 16.264
202106 9.116 271.696 11.079
202109 5.645 274.310 6.795
202112 -4.271 278.802 -5.059
202203 0.777 287.504 0.892
202206 -5.175 296.311 -5.767
202209 -7.020 296.808 -7.810
202212 -6.865 296.797 -7.638
202303 -9.605 301.836 -10.508
202306 -7.204 305.109 -7.797
202309 -5.140 307.789 -5.514
202312 -4.444 306.746 -4.784
202403 -5.489 312.332 -5.803
202406 -2.413 314.175 -2.536
202409 -2.785 315.301 -2.917
202412 -3.467 315.605 -3.627
202503 -0.413 319.799 -0.426
202506 0.189 322.561 0.193
202509 -0.768 324.800 -0.781
202512 -0.626 324.054 -0.638
202603 -0.693 330.213 -0.693

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of CHF-1.99 mean?
Novavax (XSWX:NVAX) has a Cyclically Adjusted Book per Share of CHF-1.99 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's Cyclically Adjusted Book per Share too high?
Novavax's current Cyclically Adjusted Book per Share is CHF-1.99. Overall, Novavax has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Cyclically Adjusted Book per Share compare to MPLT and COAG?
Novavax's Cyclically Adjusted Book per Share of CHF-1.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current Cyclically Adjusted Book per Share is CHF-1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Cyclically Adjusted Book per Share of CHF-1.99. The stock's GF Value™ is CHF3.14, compared to a current price of CHF7.61 — trading 142.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is CHF-1.99. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Cyclically Adjusted Book per Share is CHF-1.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.

Key valuation signals for XSWX:NVAX:

  • Cyclically Adjusted Book per Share: CHF-1.99
  • GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score

Get the complete analysis for XSWX:NVAX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.61
Price
CHF3.14
GF Value